Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL102034 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL13265455 | 0.80 | SMN1; SMN2 (0.36) | SMN1; SMN2HRH3EPHX1EPHX2 | |
| SCHEMBL102049 | 0.80 | SMN1; SMN2 (0.36) | SMN1; SMN2HRH3EPHX1EPHX2 | |
| SCHEMBL178284 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL23686080 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL10442553 | 0.78 | NCF1 (0.48) | HRH3 | |
| SCHEMBL20794138 | 0.77 | SMN1; SMN2 (0.39) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL14593696 | 0.77 | HRH3 (0.40) | HRH3 | |
| SCHEMBL16216042 | 0.75 | HRH3 (0.36) | SMN1; SMN2HRH3EPHX1EPHX2HSD11B1 | |
| SCHEMBL24865954 | 0.73 | KMT2A (0.42) | SMN1; SMN2HRH3EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885HRH3 3631/4885EPHX1 1684/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMN1; SMN2 2647/4885HRH3 3631/4885EPHX1 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.